Jose Castillo
Jose co-founded Univercells in 2013 alongside Hugues Bultot and served as CTO before founding Quantoom Biosciences in 2021 to focus specifically on scalable RNA production. Quantoom received USD 13.9 million (EUR 12.4 million) in grant funding to develop its mRNA manufacturing platform for vaccines and therapeutics.
The Nfinity platform covers DNA (Nplify), RNA (Ntensify), and formulation (Ncapsulate) manufacturing, providing a full-stack RNA partner from sequence to large-scale GMP production. Quantoom has established facilities in Belgium and France and has entered partnerships with eTheRNA immunotherapies and Stevanato Group.
Career
Roles
Quantoom BiosciencesCEOJun 2021 – Present
UnivercellsCo-Founder and CTOFeb 2013 – Present
- STRIGIDAEOwner2008 – Present
- Pall Life SciencesDirector, Cell Culture TechnologiesMar 2014 – Dec 2014
- MasthercellChairman of the Board of Directors2011 – 2014
OvizioMember of the Board of Directors2011 – 2015
- ATMI#427factoryGlobal Director, Cell Culture TechnologiesNov 2010 – Mar 2014
- Artelis#535factoryFounder and CTOAug 2005 – Oct 2010
- GSK#31factoryManager - Viral Vaccines IndustrializationAug 1999 – Dec 2004
Education
Solvay Brussels School of Economics and Management#6schoolEntrepreneurship1998 - 1999
Université libre de Bruxelles#10schoolPhD Applied Sciences & Chemical Engineering degree, Sciences appliquées1987 - 1996
From public career histories · 11 entries